S
Shukra Pharmaceuticals Ltd
BSE:524632
Shukra Pharmaceuticals Ltd
BSE:524632
Price:
29.07
INR
0.03%
Market Cap:
₹12.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
24.3
Current
3 211%
More Expensive
vs 3-y average of 0.7
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
EV/GP
=
24.3
Enterprise Value
/
₹16.8B
Gross Profit
₹520m
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
EV/GP
=
24.3
Enterprise Value
/
₹16.8B
Gross Profit
₹520m
Valuation Scenarios
Shukra Pharmaceuticals Ltd is trading
above
its 3-year average
If EV/GP returns to its 3-Year Average (0.7), the stock would be worth ₹0.88 (97% downside from current price).
Statistics
Positive Scenarios
0/4
Maximum Downside
-98%
Maximum Upside
No Upside Scenarios
Average Downside
85%
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 24.3 | ₹29.07 |
0%
|
| 3-Year Average | 0.7 | ₹0.88 |
-97%
|
| 5-Year Average | 0.6 | ₹0.67 |
-98%
|
| Industry Average | 6.5 | ₹7.84 |
-73%
|
| Country Average | 6.5 | ₹7.84 |
-73%
|
Forward EV/GP
Today’s price vs future gross profit
Not enough data available to calculate forward EV/GP
Peer Comparison
All Countries
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
S
|
Shukra Pharmaceuticals Ltd
BSE:524632
|
12.7B INR | 24.3 | 43.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 16.9 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 8.8 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 6.3 | 27.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 5.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 7.4 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 5.2 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 4.2 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 4.4 | 17.3 |
EV/GP Multiple
P/E Multiple
Market Distribution
Higher than 91% of
companies
in
India
Percentile
91th
Based on 2 475 companies
S
91th percentile
24.3
Low
0.2 — 4.1
Typical Range
4.1 — 10.8
High
10.8
—
∞
Distribution Statistics
India
| Min | 0.2 |
| 30th Percentile | 4.1 |
| Median | 6.5 |
| 70th Percentile | 10.8 |
| Max | 34 392.2 |
Other Multiples
Shukra Pharmaceuticals Ltd
Glance View
The company is headquartered in Ahmedabad, Gujarat.
SHUKRAPHAR
Intrinsic Value
1.96
INR
Overvaluation 93%
S
